Key facts, as of
As of September 29, 2026, Insulet Corporation (PODD) trades at $132.84, down 57.2% over the past year. Its 52-week range runs from $126.40 to $354.88; the price is 62.6% below that high. It sits 32.2% below its 200-day average of $195.82, the usual sign of a long-term downtrend. Its 30-day volatility is 28.7% annualized, which we rate medium risk. It has a trailing P/E of 24.9.
Cite: Portfolio Terminal, "Insulet Corporation (PODD) stock analysis", 2026-09-29. https://portfolio-terminal.com/analyse/podd
Where it trades today
trading 3% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- PODD is valued near its sector range at 24.9x earnings versus 22.0x for peers, so the next move likely needs a real earnings or guidance catalyst.
- Recent realized volatility is running around 28.7%, above the sector norm of 22.0%, so position sizing matters more than usual.
- PODD remains in a bearish short-term trend and sits 62.6% below its high, which raises the bar for any thesis that depends on fast multiple expansion.
Portfolio Use Case
- PODD is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The risk profile looks balanced enough for a diversified core-plus portfolio, provided the position size reflects sector concentration.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in PODD.
- A recovery in price alone would not be enough to improve the view; the thesis needs confirmation from improving business or valuation signals.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
Methodology
- Price, market cap, beta, yield, and liquidity fields for PODD come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for PODD. Last refresh: Sep 29, 2026, 10:33 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Insulet Corporation does
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also…
What analysts expect
PODD carries a buy consensus from 22 analysts, with an average price target of $171.91 versus $132.84 today (+29.4%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
PODD generated $3.05B in trailing revenue (23.5% year over year), with a 12.3% net margin, and $236.90M of free cash flow, against $413.50M of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $2.71B | $1.94B | $473.80M | $247.10M | $3.51 | $349.90M |
| 2024 | $2.07B | $1.45B | $308.90M | $418.30M | $5.97 | $296.20M |
| 2023 | $1.70B | $1.16B | $220.10M | $206.30M | $2.96 | $36.50M |
| 2022 | $1.31B | $805.60M | $37.60M | $4.60M | $0.07 | -$38.30M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
PODD beside the healthcare names it is usually measured against.
What the chart is saying
In a downtrend, below both moving averages.
downtrend- Price is 9.6% below its 50-day average and 32.2% below its 200-day.
- RSI at 36 is neither stretched nor washed out.
- The nearest ceiling is $139.67 (+5.1%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is PODD a good buy right now?
Insulet Corporation trades at 24.9x earnings. This is near market average. Current risk level is Medium based on 28.7% volatility.
Does PODD pay dividends?
Insulet Corporation does not currently pay a regular dividend. The company may be reinvesting profits for growth.
How volatile is PODD?
With 30-day annualized volatility of 28.7% and beta of 1.08, PODD is classified as Medium risk. Expect larger swings than the broader market during volatile periods.
What is the analyst price target for PODD?
The average analyst price target for Insulet Corporation (PODD) is $171.91 based on 22 analyst estimates, about 29.4% above the current price of $132.84. The published range runs from $144.00 to $275.00.
How much revenue does PODD generate?
Insulet Corporation reported $3.05B in trailing twelve-month revenue. Revenue growth is running at 23.5% year over year. Net margin sits at 12.3%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare PODD with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.